search button

Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma

  • Authors:
    • Hong-Gang Xiang
    • Xiao Xie
    • Feng-Qing Hu
    • Hai-Bo Xiao
    • Wen-Jie Zhang
    • Lei Chen

  • View Affiliations

  • Published online on: July 2, 2014     https://doi.org/10.3892/or.2014.3301
  • Pages: 1140-1148
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cyclooxygenase-2 (COX-2) has been proven to play critical roles in inflammation as well as in cancer. Some studies have shown that the anti-inflammatory, immunosuppressive and anti-arthritic effects of celecoxib are mainly attributed to the inhibition of COX-2 expression. The present study aimed to investigate the function of COX-2 in human gastric adenocarcinoma (GAC). Forty-five cases of human GAC tissues and corresponding adjacent non-cancerous tissues (ANCTs) were collected. The expression of COX-2 and proliferating cell nuclear antigen (PCNA) was assessed using immunohistochemical assay through a tissue microarray procedure. GAC cells (SGC-7901 and MKN-45) in vitro were treated with COX-2 siRNA or different concentrations of celecoxib to observe their effects on cell proliferation, invasion and the underlying molecular mechanisms. As a consequence, the expression of COX-2 and PCNA was found in cancer tissues with a higher strong reactivity rate, compared with the ANCTs (80.0 vs. 53.3%, P=0.011; 68.9 vs. 48.9%, P=0.047), and COX-2 was positively associated with lymph node metastasis of GAC patients (P=0.011). Targeted knockdown of COX-2 inhibited the proliferation, migration and invasion of GAC cells with decreased expression of PCNA. COX-2 inhibitor celecoxib also suppressed the proliferative activities of GAC cells with decreased expression of COX-2 and PCNA. In addition, the tumor volume in the MKN-45 subcutaneous tumor model treated with siCOX-2 was significantly smaller than that of the negative control (NC) group (P<0.01). Taken together, our findings offer a strong preclinical rationale to target COX-2 signaling as a therapeutic strategy to improve the treatment of gastric adenocarcinoma.
View Figures
View References

Related Articles

Journal Cover

September-2014
Volume 32 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Xiang H, Xie X, Hu F, Xiao H, Zhang W and Chen L: Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma. Oncol Rep 32: 1140-1148, 2014
APA
Xiang, H., Xie, X., Hu, F., Xiao, H., Zhang, W., & Chen, L. (2014). Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma. Oncology Reports, 32, 1140-1148. https://doi.org/10.3892/or.2014.3301
MLA
Xiang, H., Xie, X., Hu, F., Xiao, H., Zhang, W., Chen, L."Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma". Oncology Reports 32.3 (2014): 1140-1148.
Chicago
Xiang, H., Xie, X., Hu, F., Xiao, H., Zhang, W., Chen, L."Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma". Oncology Reports 32, no. 3 (2014): 1140-1148. https://doi.org/10.3892/or.2014.3301